Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Saran

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Journal of Neuro-Oncology|July 17, 2022
Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiationAkifumi Hagiwara, Jacob Schlossman, Soroush Shabani, et al.
Nuclear Medicine Communications|January 28, 2016
Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastomaSally L George, Nadia Falzone, Sarah Chittenden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 7, 2018
SIOPE - Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapyThankamma Ajithkumar, Gail Horan, Laetitia Padovani, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and ResearchersGeorgia K B Halkett, Lauren J Breen, Melissa Berg, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
Pediatric Blood & Cancer|August 15, 2015
The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy)Sindu Vivekanandan, Richard Breene, Ramya Ramanujachar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2018
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade GliomaJacques Grill, Maura Massimino, Eric Bouffet, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2012
Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysisGeert O Janssens, Marc H Jansen, Selmer J Lauwers, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Journal of Neuro-Oncology|July 17, 2022
Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiationAkifumi Hagiwara, Jacob Schlossman, Soroush Shabani, et al.
Nuclear Medicine Communications|January 28, 2016
Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastomaSally L George, Nadia Falzone, Sarah Chittenden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 7, 2018
SIOPE - Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapyThankamma Ajithkumar, Gail Horan, Laetitia Padovani, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and ResearchersGeorgia K B Halkett, Lauren J Breen, Melissa Berg, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
Pediatric Blood & Cancer|August 15, 2015
The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy)Sindu Vivekanandan, Richard Breene, Ramya Ramanujachar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2018
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade GliomaJacques Grill, Maura Massimino, Eric Bouffet, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2012
Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysisGeert O Janssens, Marc H Jansen, Selmer J Lauwers, et al.
Pageof 8